By Scientia Professor Vlado Perkovic

Book Chapters

Rahimi K; Perkovic V, 2018, 'Meta-Analyses of Blood Pressure Lowering Trials and the Blood Pressure Lowering Treatment Trialists' Collaboration', in Hypertension A Companion to Braunwald S Heart Disease, pp. 433 - 441, http://dx.doi.org/10.1016/B978-0-323-42973-3.00047-0

Rahimi K; Perkovic V, 2018, '47 Meta-Analyses of Blood Pressure Lowering Trials and the Blood Pressure Lowering Treatment Trialists’ Collaboration', in Hypertension: A Companion to Braunwald's Heart Disease, Elsevier, pp. 433 - 441, http://dx.doi.org/10.1016/b978-0-323-42973-3.00047-0

Jun M; Perkovic V, 2015, 'Fibrates: risk-benefits and role in treating dyslipidemias', in Dyslipidemias Pathophysiology, Evaluation and Management, Humana Press

Wang AY; Jardine M; Perkovic V, 2014, 'Kidney Disease in Diabetes', in Managing Cardiovascular Complications in Diabetes, pp. 58 - 86, http://dx.doi.org/10.1002/9781118337967.ch3

Wang Y; Perkovic V; Jardine M, 2014, 'kidney disease in diabetes', in Managing Cardiovascular Complications in Diabetes, John Wiley & Sons

Wang Y; Ivany JN; Perkovic V; Gallagher MP; Jardine MJ, 2012, 'Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney disease', in Wang Y (ed.), , John Wiley & Sons, Ltd, http://dx.doi.org/10.1002/14651858.cd009631

Gangadharan Komala M; Pianta TJ; Jardine MJ; Webster AC; Perkovic V, 2011, 'Interventions for preventing intradialytic hypotension in haemodialysis patients', in Gangadharan Komala M (ed.), , John Wiley & Sons, Ltd, http://dx.doi.org/10.1002/14651858.cd009459

Jun M; Perkovic V; Cass A, 2011, 'Intensive glycemic control and renal outcome', in Diabetes and the Kidney, Karger Medical and Scientific Publishers

Razavian M; Di Micco L; Palmer SC; Craig JC; Perkovic V; Zoungas S; Webster AC; Jardine MJ; Strippoli GFM, 2010, 'Antiplatelet agents for chronic kidney disease', in Palmer SC (ed.), , John Wiley & Sons, Ltd, http://dx.doi.org/10.1002/14651858.cd008834

Badve SV; Beller E; Cass A; Francis DP; Hawley C; Macdougall IC; Perkovic V; Johnson DW, 2010, 'Interventions for erythropoietin-resistant anaemia in dialysis patients', in Badve SV (ed.), , John Wiley & Sons, Ltd, http://dx.doi.org/10.1002/14651858.cd006861.pub2

Perkovic V; Venkataraman V; Cooper B; Zoungas S; Webster AC, 2009, 'Antioxidants for chronic kidney disease', in Perkovic V (ed.), , John Wiley & Sons, Ltd, http://dx.doi.org/10.1002/14651858.cd008176

Gallagher M; Perkovic V; Jardine M; Cass A, 2009, 'Lipid lowering in chronic kidney disease', in Therapeutic Strategies in Lipid Disorders

Perkovic V; Craig JC; Masterson R; Webster A, 2004, 'HMG CoA reductase inhibitors (statins) for kidney transplant recipients', in Perkovic V (ed.), , John Wiley & Sons, Ltd, http://dx.doi.org/10.1002/14651858.cd005019

Journal articles

Lee MMY; Sattar N; Pop-Busui R; Deanfield J; Emerson SS; Inzucchi SE; Mann JFE; Marx N; Mulvagh SL; Poulter NR; Badve SV; Pratley RE; Perkovic V; Buse JB; McGuire DK, 2025, 'Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials', Diabetes Care, 48, pp. 846 - 859, http://dx.doi.org/10.2337/dc25-0241

Koshino A; Heerspink HJL; Jongs N; Badve SV; Arnott C; Neal B; Jardine M; Mahaffey KW; Pollock C; Perkovic V; Hansen MK; Bakker SJL; Wada T; Neuen BL, 2025, 'Canagliflozin and iron metabolism in the CREDENCE trial', Nephrology Dialysis Transplantation, 40, pp. 696 - 706, http://dx.doi.org/10.1093/ndt/gfae198

Siriwardana A; Buizen L; Jun M; Kotwal S; Arnott C; Jardine MJ; Levin A; Heerspink HJL; Charytan DM; Pollock C; Perkovic V; Neuen BL, 2025, 'Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trial', Diabetes Obesity and Metabolism, 27, pp. 1972 - 1979, http://dx.doi.org/10.1111/dom.16190

Chan B; Varghese A; Badve SV; Pecoits-Filho R; Guedes M; Arnott C; Kozor R; O'Lone E; Jun M; Kotwal S; Block GA; Chertow GM; Solomon SD; Vaduganathan M; Perkovic V; Neuen BL, 2025, 'Systematic Review of the Effects of Iron on Cardiovascular, Kidney, and Safety Outcomes in Patients With CKD', Kidney International Reports, 10, pp. 1037 - 1049, http://dx.doi.org/10.1016/j.ekir.2025.01.029

Mahaffey KW; Tuttle KR; Arici M; Baeres FMM; Bakris G; Charytan DM; Cherney DZI; Chernin G; Correa-Rotter R; Gumprecht J; Idorn T; Pugliese G; Rasmussen IKB; Rasmussen S; Rossing P; Sokareva E; Mann JFE; Perkovic V; Pratley R, 2025, 'Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial', European Heart Journal, 46, pp. 1096 - 1108, http://dx.doi.org/10.1093/eurheartj/ehae613

Siriwardana A; Smyth B; Jardine M, 2025, 'Waiver of informed consent in clinical research: a summary of contemporary guidelines and a resource for researchers', BMJ Open, 15, http://dx.doi.org/10.1136/bmjopen-2024-091896

Webster ER; Perkovic A; Neuen BL; Tuttle KR; Perkovic V, 2025, 'Effects of anti-inflammatory agents on clinical outcomes in people with chronic kidney disease: a systematic review and meta-analysis of randomized control trials', Clinical Kidney Journal, 18, http://dx.doi.org/10.1093/ckj/sfaf001

Beal B; Buizen L; Yeung EK; Heath L; Houston L; Cherney DZI; Jardine M; Pollock C; Arnott C; Kotwal SS; Heerspink HJL; Perkovic V; Neuen BL, 2025, 'Effects of SGLT2 inhibition on insulin use in CKD and type 2 diabetes: Insights from the CREDENCE trial.', Nephrol Dial Transplant, http://dx.doi.org/10.1093/ndt/gfaf044

Perkovic V; Barratt J; Rovin B; Kashihara N; Maes B; Zhang H; Trimarchi H; Kollins D; Papachristofi O; Jacinto-Sanders S; Merkel T; Guerard N; Renfurm R; Hach T; Rizk DV, 2025, 'Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy', New England Journal of Medicine, 392, pp. 531 - 543, http://dx.doi.org/10.1056/NEJMoa2410316

Heerspink HJL; Agarwal R; Bakris GL; Cherney DZI; Lam CSP; Neuen BL; Sarafidis PA; Tuttle KR; Wanner C; Brinker MD; Dizayee S; Kolkhof P; Schloemer P; Vesterinen P; Perkovic V; Bittar J; Zaidman CJ; Cluigt N; Hominal M; Aguerre P; Halac F; Gelersztein E; Arriola M; Maldonado R; Chahin M; Packham D; Lee D; Pedagogos E; Foote C; Badve S; Hawley C; Chen J; Gray N; Speeckaert M; Labriola L; Doubel P; Maes B; Claes K; Dubois B; Dimitrova I; Vutova T; Ilchev S; Stamova S; Ivanova Y; Vasileva A; Chen X; Tang S; Xu X; Liu B; He W; He Y; Liu F; Wang C; Chen L; Niu J; Wang D; Luo P; Xia Y; Jiang G; Luo Q; Wang F; Chen M; Lin H; Yan R; Li Y; Chen Q; Dong J; Xiong F; Long H; Cheng H; Li Y; Du J; Liu F; Chen Q; Lu W; Chen C; Wang J; Liu L; Yang M; Long G; Shi Y; Li W; Yang X; Yang A; Li J; Meng X; Prazny M; Hornova L; Bucek P; Majernikova M; Wirth J; Rehorova J; Hornum M; Bech J; Lindhardt M; Hansen D; Mortensen L; Juhl C; Boletis I; Papadopoulou D, 2025, 'Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial', Nephrology Dialysis Transplantation, 40, pp. 308 - 319, http://dx.doi.org/10.1093/ndt/gfae132

Kotwal SS; Perkovic V, 2025, 'Effects of Semaglutide on CKD in Patients With Type 2 Diabetes', Kidney International Reports, 10, pp. 287 - 290, http://dx.doi.org/10.1016/j.ekir.2024.11.1365

Chatur S; Vaduganathan M; Fletcher RA; Perkovic V; Heerspink H; Arnott C; Pollock C; Mahaffey KW; Neal B; Jardine M; Solomon SD; Neuen BL, 2025, 'Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant-level pooled analysis of the CANVAS and CREDENCE trials', European Journal of Heart Failure, http://dx.doi.org/10.1002/ejhf.3586

Badve SV; Bilal A; Lee MMY; Sattar N; Gerstein HC; Ruff CT; McMurray JJV; Rossing P; Bakris G; Mahaffey KW; Mann JFE; Colhoun HM; Tuttle KR; Pratley RE; Perkovic V, 2025, 'Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials', Lancet Diabetes and Endocrinology, 13, pp. 15 - 28, http://dx.doi.org/10.1016/S2213-8587(24)00271-7

Jeyaruban A; Bose B; Lee VW; Jardine M; Mallawaarachchi A; Ritchie A; Wong MG; Makris A; Badve S; Siriwardana A; Yong K; Perkovic V; Kotwal S, 2025, 'Glomerular disease registry and biobank: design and baseline results', Internal Medicine Journal, http://dx.doi.org/10.1111/imj.70056

Nguyen TN; Yu J; Perkovic V; Jardine M; Mahaffey KW; Chow CK; Arnott C; Lindley RI, 2025, 'The Efficacy and Safety of Canagliflozin by Frailty Status in Participants of the CANVAS and CREDENCE Trials', Journal of the American Geriatrics Society, http://dx.doi.org/10.1111/jgs.19444

Talbot B; Davies S; Burman J; Ritchie A; Snelling P; Lynch S; Park Y; Jones B; Garvey V; Jaure A; Jardine M; Perkovic V; Gallagher M; Brandwood A; Kaur N; Knight J, 2025, 'The Point-of-Care Peritoneal Dialysis System Early Evaluation Study (POC-PDEE): A pilot proof-of-principal study of the Ellen Medical Devices Point-of-Care affordable peritoneal dialysis system', Peritoneal Dialysis International, 45, pp. 52 - 56, http://dx.doi.org/10.1177/08968608231209850

Odler B; Riedl R; Geetha D; Szpirt WM; Hawley C; Uchida L; Wallace ZS; Walters G; Muso E; Tesar V; Pusey CD; Little MA; Merkel PA; Walsh M; Jayne DRW; Kronbichler A; PEXIVAS Investigators , 2025, 'The effects of plasma exchange and glucocorticoids on early kidney function among patients with ANCA-associated vasculitis in the PEXIVAS trial.', Kidney Int, 107, pp. 558 - 567, http://dx.doi.org/10.1016/j.kint.2024.11.029

Kotwal S; Jeyaruban A; Bose B; Lee V; Jardine M; MALLAWARCHCHI A; Ritchie A; Wong M-G; Makris A; Badve S; Siriwardana A; Yong K; Perkovic V, 2025, 'WCN25-1567 Glomerular disease registry and Biobank (GRIT)– design and baseline results', Kidney International Reports, 10, pp. S196 - S197, http://dx.doi.org/10.1016/j.ekir.2024.11.382

Kotwal S; Perkovic V; Jardine M; Vart P; Wheeler D; de Boer I; Zhang H; Hou FF; Sugawara Y; De Nicola L; Gorriz J; Heerspink H, 2025, 'WCN25-1572 DESIGN AND BASELINE CHARACTERISTICS OF THE GLOBAL KIDNEY PATIENT TRIALS NETWORK', Kidney International Reports, 10, pp. S287 - S288, http://dx.doi.org/10.1016/j.ekir.2024.11.535

Tuttle K; Arici M; Arslan EG; Bellary S; Idorn T; Ji L; Kamenov Z; Kashihara N; Mann J; Mahaffey K; Perkovic V; Rasmussen S; Rossing P; Schytz PA; Sreenivasamurthy L; Pratley R, 2025, 'WCN25-1900 Clinical and Safety Outcomes of Semaglutide by CKD Severity in the FLOW trial', Kidney International Reports, 10, pp. S770 - S770, http://dx.doi.org/10.1016/j.ekir.2024.11.1358

Lafayette R; Trimarchi H; Barratt J; Carroll K; Tesar V; Zhang H; Suzuki Y; Liew A; Wong MG; Shah L; Xia J; Fajaro C; Hafkin J; Perkovic V, 2025, 'WCN25-499 PATIENT BASELINE CHARACTERISTICS IN THE ONGOING PHASE 3 VISIONARY TRIAL: A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF SIBEPRENLIMAB FOR IMMUNOGLOBULIN A NEPHROPATHY', Kidney International Reports, 10, pp. S158 - S159, http://dx.doi.org/10.1016/j.ekir.2024.11.328

Kollins D; Papachristofi O; Hach T; Valentin M-A; Merkel T; Renfurm R; Perkovic V, 2025, 'WCN25-716 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS IN IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE PHASE 3 APPLAUSE-IgAN STUDY', Kidney International Reports, 10, pp. S177 - S177, http://dx.doi.org/10.1016/j.ekir.2024.11.358

Kollins D; Papachristofi O; Hach T; Jacinto-Sanders S; Merkel T; Schmouder R; Kulmatycki K; Renfurm R; Perkovic V, 2025, 'WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS', Kidney International Reports, 10, pp. S183 - S184, http://dx.doi.org/10.1016/j.ekir.2024.11.362

Kollins D; Papachristofi O; Hach T; Jacinto-Sanders S; Merkel T; Renfurm R; Perkovic V, 2025, 'WCN25-799 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IgAN STUDY', Kidney International Reports, 10, pp. S184 - S184, http://dx.doi.org/10.1016/j.ekir.2024.11.363

Perkovic V; Tuttle K; Sattar N; Lincoff AM; Navar AM; Marx N; Hvelplund A; Baeres FMM; Engelmann MD; Hovingh GK; Ridker PM, 2025, 'WCN25-888 DESIGN OF THE ZEUS TRIAL: INTERLEUKIN 6 INHIBITION WITH ZILTIVEKIMAB FOR CARDIOVASCULAR PROTECTION IN CHRONIC KIDNEY DISEASE', Kidney International Reports, 10, pp. S767 - S768, http://dx.doi.org/10.1016/j.ekir.2024.11.1354

Kotwal SS; Perkovic V; Jardine MJ; Kim D; Shah NA; Lin E; Coggan S; Billot L; Vart P; Wheeler DC; De Boer IH; Zhang H; Hou FF; Sugawara Y; Marion J; Lewis RJ; Berry LR; McGlothlin A; Jha V; De Nicola L; Gorriz JL; Heerspink HJL, 2024, 'The Global Kidney Patient Trials Network and the CAPTIVATE Platform Clinical Trial Design: A Trial Protocol', JAMA Network Open, 7, http://dx.doi.org/10.1001/jamanetworkopen.2024.49998

Heerspink HJL; Perkovic V; Tuttle KR; Pergola PE; Mahaffey KW; Patel UD; Ishida JH; Kuo A; Chen F; Kustra R; Petrovic V; Rossing P; Kashihara N; Chertow GM, 2024, 'Selonsertib in Patients with Diabetic Kidney Disease: A Phase 2b Randomized Active Run-In Clinical Trial', Journal of the American Society of Nephrology, 35, pp. 1726 - 1736, http://dx.doi.org/10.1681/ASN.0000000000000444

Neuen BL; Ostrominski JW; Claggett B; Beldhuis IE; Chatur S; McCausland FR; Badve SV; Arnott C; Heerspink HJL; Jun M; Falster M; de Oliveira Costa J; Pollock C; Jardine MJ; Mahaffey KW; Perkovic V; Solomon SD; Vaduganathan M, 2024, 'Bidirectional Relationship Between Kidney Disease Progression and Cardiovascular Events in Type 2 Diabetes', Journal of the American College of Cardiology, 84, pp. 2246 - 2250, http://dx.doi.org/10.1016/j.jacc.2024.08.006

Neuen BL; Fletcher RA; Heath L; Perkovic A; Vaduganathan M; Badve SV; Tuttle KR; Pratley R; Gerstein HC; Perkovic V; Heerspink HJL, 2024, 'Cardiovascular, Kidney, and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis', Circulation, 150, pp. 1781 - 1790, http://dx.doi.org/10.1161/CIRCULATIONAHA.124.071689

Perkovic V; Tuttle KR; Pratley R, 2024, 'Semaglutide for Chronic Kidney Disease in Type 2 Diabetes. Reply', New England Journal of Medicine, 391, pp. 1757, http://dx.doi.org/10.1056/NEJMc2410532

Neuen BL; Ostrominski JW; Claggett BL; Beldhuis I; Chatur S; Arnott C; Heerspink HJL; Pollock C; Jardine M; Mahaffey KW; Perkovic V; Solomon SD; Vaduganathan M, 2024, 'Bidirectional relationship between kidney disease progression and cardiovascular events in type 2 diabetes: new Insights from the CANVAS Program and CREDENCE trial', European Heart Journal, 45, http://dx.doi.org/10.1093/eurheartj/ehae666.3264

Chatur S; Neuen BL; Fletcher RA; Perkovic V; Heerspink H; Arnott C; Pollock C; Mahaffey KW; Neal B; Jardine M; Solomon SD; Vaduganathan M, 2024, 'Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: a participant level pooled analysis of CREDENCE and CANVAS', European Heart Journal, 45, pp. ehae666.1228, http://dx.doi.org/10.1093/eurheartj/ehae666.1228

Pratley RE; Tuttle KR; Rossing P; Rasmussen S; Perkovic V; Nielsen OW; Mann JFE; MacIsaac RJ; Kosiborod MN; Kamenov Z; Idorn T; Hansen MB; Hadjadj S; Bakris G; Baeres FMM; Mahaffey KW, 2024, 'Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial', Journal of the American College of Cardiology, 84, pp. 1615 - 1628, http://dx.doi.org/10.1016/j.jacc.2024.08.004

Li J; Lv J; Wong MG; Shi S; Zan J; Monaghan H; Perkovic V; Zhang H; Agarwal R; Barbour S; Cattran D; Cass A; Chan TM; Feehally J; Glassock R; Hladunewich MA; Hooi LS; Jardine MJ; Jha V; Johnson DW; Levin A; Liu ZH; Reich H; Remuzzi G; Wheeler DC; Wong MG; Woodward M; Wu Y; Zhao M, 2024, 'Correlation of Urinary Soluble CD163 Levels With Disease Activity and Treatment Response in IgA Nephropathy', Kidney International Reports, 9, pp. 3016 - 3026, http://dx.doi.org/10.1016/j.ekir.2024.07.031

Mann JFE; Rossing P; Bakris G; Belmar N; Bosch-Traberg H; Busch R; Charytan DM; Hadjadj S; Gillard P; Górriz JL; Idorn T; Ji L; Mahaffey KW; Perkovic V; Rasmussen S; Schmieder RE; Pratley RE; Tuttle KR, 2024, 'Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial', Nature Medicine, 30, pp. 2849 - 2856, http://dx.doi.org/10.1038/s41591-024-03133-0

Kotwal SS; Dip G; Perkovic V, 2024, 'Kidney Disease as a Cardiovascular Disease Priority', Circulation, 150, pp. 975 - 977, http://dx.doi.org/10.1161/CIRCULATIONAHA.124.068242

Vaduganathan M; Cannon CP; Jardine MJ; Heerspink HJL; Arnott C; Neuen BL; Sarraju A; Gogate J; Seufert J; Neal B; Perkovic V; Mahaffey KW; Kosiborod MN, 2024, 'Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant-level pooled analysis from the CANVAS Program and CREDENCE trial', European Journal of Heart Failure, 26, pp. 1967 - 1975, http://dx.doi.org/10.1002/ejhf.3292

Back to profile page